Thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
By the early 1980s, the USSR had built up a military arsenal and army surpassing that of the United States. Soon after the Soviet invasion of Afghanistan, President Carter began massively building up the United States military. This buildup was accelerated by the Reagan administration, which increased the military spending from 5.3 percent of GNP in 1981 to 6.5 percent in 1986, the largest peacetime defense buildup in United States history. The American-Soviet tensions present during 1983 was defined by some as the start of "Cold War II". While in retrospective this phase of the Cold War was generally defined as a "war of words", the Soviet's "peace offensive" was largely rejected by the West. Tensions continued to intensify as Reagan revived the B-1 Lancer program, which had been canceled by the Carter administration, produced LGM-118 Peacekeeper missiles, installed US cruise missiles in Europe, and announced the experimental Strategic Defense Initiative, dubbed "Star Wars" by the media, a defense program to shoot down missiles in mid-flight. The Soviets deployed RSD-10 Pioneer ballistic missiles targeting Western Europe, and NATO decided, under the impetus of the Carter presidency, to deploy MGM-31 Pershing and cruise missiles in Europe, primarily West Germany. This deployment placed missiles just 10 minutes' striking distance from Moscow.
=== Water purification === NASA engineers are collaborating with qualified companies to develop systems intended to sustain the astronauts living on the International Space Station and future Moon and space missions. This system turns wastewater from respiration, sweat, and urine into drinkable water. By combining the benefits of chemical adsorption, ion exchange, and ultra-filtration processes, this technology can yield safe, drinkable water from the most challenging sources, such as in underdeveloped regions where well water may be heavily contaminated.
In its half yearly financial report on 26 August 2021, Irish Continental Group, which operates ferries between Great Britain and the Republic of Ireland, expressed concern at the lack of implementation of checks on goods arriving into Northern Ireland from Great Britain, as required under the protocol. The company said that the continued absence of these checks (on goods destined for the Republic of Ireland) is causing a distortion of the level playing field, since goods that arrive directly at the Republic of Ireland's ports from Great Britain are checked on arrival. The implementation of border controls between Great Britain and Northern Ireland was the primary catalyst for the 2021 Northern Ireland riots. An unusual example of internal border controls pertains to customs enforcement within the Schengen area. Even though borders are generally invisible, the existence of areas within the Schengen area but outside the European Union Value Added Tax Area, as well as jurisdictions such as Andorra which are not officially a part of the Schengen area but can not be accessed without passing through it, has resulted in the existence of sporadic internal border controls for customs purposes. Additionally, as per Schengen area rules, hotels and other types of commercial accommodation must register all foreign citizens, including citizens of other Schengen states, by requiring the completion of a registration form by their own hand.
Secondhand smoke is tobacco smoke which affects people other than the 'active' smoker. It is made up of the exhaled smoke (15%) and mostly of smoke coming from the burning end of the cigarette, known as sidestream smoke (85%). Secondhand smoke contains more than 7000 chemicals, of which hundreds are harmful to health. Secondhand tobacco smoke includes both a gaseous and a particulate materials which, with particular hazards arising from levels of carbon monoxide and small particulates (fine particulate matter, especially PM2.5 and PM10) which get into the bronchioles and alveoles in the lung. Inhaling secondhand smoke on multiple occasions can cause asthma, pneumonia, lung cancer, and sudden infant death syndrome, among other conditions. Thirdhand smoke (THS) refers to chemicals that settle on objects and bodies indoors after smoking. Exposure to thirdhand smoke can happen even after the actual cigarette smoke is not present anymore and affect those entering the indoor environment much later. Toxic substances of THS can react with other chemicals in the air and produce new toxic chemicals that are otherwise not present in cigarettes. The only certain method to improve indoor air quality as regards secondhand smoke is to eliminate smoking indoors. Indoor e-cigarette use also increases home particulate matter concentrations.
Sources: en.wikipedia.org
Solvent assisted inlet ionization (SAII) is similar to matrix-assisted inlet ionization however the matrix is a solvent such as water, acetonitrile and methanol. This ionization technique is highly sensitive to small molecules, peptides and proteins. The analyte is dissolved in the solvent and can either be introduced to the heated inlet tube by a capillary column or directly injected into the inlet tube with a syringe or by pipetting. The capillary column is made of fused silica particles with one end submerged in the sample solvent and the other in the end of the heated inlet tube. The solvent flows through the capillary column without the use of a pump due to the pressure difference between ambient pressure and the vacuum. The temperature can vary in the inlet tube from 50 °C to 450 °C, with the lower temperature being used if the results obtained from a higher temperature are of good resolution. Solvent assisted inlet ionization can be coupled not only to liquid chromatography (LC) but also to nano LC.
=== Guest === Christian Kane as Jacob Stone, one of the Librarians from the Portland, Oregon Annex who specializes in archaeology, art history, and architecture. He was introduced in The Librarians. Arielle Dombasle as Dame Anna Mirinoff (season 1) Celyn Jones as Cupid, God of Love; Vikram's friend (season 1) Ike Bennett as Pedro Worth, a friend of Connor Green (season 1) Hannah Devlin as Hermione Palvis, a descendant of the ancient Greek Muses who can make art come alive (season 1) Philip Rosch as Sir Lancelot du Lac (season 1), Elaine's former lover and fellow ex-knight of Camelot, who became immortal along with her when they summoned the power of his shield during a battle in Medieval times. Matt Frewer played Lancelot living as a 21st-century man and using the name "Dulaque" in The Librarians, serving as the main antagonist of the first season, with Jerry O'Connell playing his younger self.
=== Mechanism === The use of NPWT to enhance wound healing is thought to be by removing excess extracellular fluid and decreasing tissue edema, which leads to increased blood flow and stabilization of the wound environment. A reduction in systemic (e.g. interleukins, monocytes) and local mediators of inflammation has been demonstrated in experimental models, while decreased matrix metalloproteinase activity and bacterial burden have been documented clinically. In vivo, NPWT has been shown to increase fibroblast proliferation and migration, collagen organization, and to increase the expression of vascular endothelial growth factor and fibroblast growth factor-2, thereby enhancing wound healing.
Sources: en.wikipedia.org
=== Indirect separation of enantiomer === Indirect enantiomer separation involves the interaction between the chiral analyte (CA) of interest and the suitable reactive CS (in this case it is an enantiopure chiral derivatizing agent, CDA) leading to the formation of a covalent diastereomeric complex that can be separated with an achiral chromatographic technique. Therapeutic agents often contain reactive functional groups (amino, hydroxyl, epoxy, carbonyl and carboxylic acid, etc.) in their structures. They are converted into covalently bonded diastereomeric derivatives using enantiomerically pure chiral derivatizing agent. The diastereomers thus formed unlike enantiomers, exhibit different physicochemical properties in an achiral environment and are eventually separated as a result of differential retention time on a stationary phase. The success of this approach depends on the availability of stable enantiopure chiral derivatizing agent (CDA) and on the presence of a suitable reactive functional group in the chiral drug molecule for covalent formation of diastereomeric derivative. The reaction of a racemic, (R,S)- Drug with a chirally and chemically pure chiral derivatizing agent, (R')-CDA, will afford diastereomeric products, (R)-Drug-(R')-CDA + (S)-Drug-(R')- CDA. The chiral derivatization reaction scheme is illustrated in the box on the right hand side. In contrast to enantiomers, diastereomers have different physicochemical properties that make them separable on regular achiral stationary phases.
=== Whole body counter === Since 2003, whole-body counters have been used in radiation protection to monitor the absorption (incorporation) of radionuclides in people who handle gamma-emitting open radioactive materials and who may be contaminated through food, inhalation of dusts and gases, or open wounds. (α and β emitters are not measurable).
== Peptidoglycan as a danger signal among bacteria == A 2025 study reported that peptidoglycan fragments released from lysed bacterial cells can function as a general danger signal among diverse bacterial species. Exposure to exogenous peptidoglycan was shown to rapidly induce the formation of three‑dimensional biofilms in Vibrio cholerae, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii and Enterococcus faecalis. Even brief exposure was sufficient to trigger a regulated response leading to increased production of biofilm matrix components. In V. cholerae, peptidoglycan exposure upregulated several genes involved in matrix synthesis, including the vps‑I and vps‑II gene clusters that contribute to biofilm structure. The mechanism by which bacteria sense extracellular peptidoglycan fragments remains unknown.
== Genetics == The human OPRK1 gene is located on chromosome 8 and comprises four exons separated by three introns, spanning approximately 25 kilobases. The gene utilizes at least three transcription initiation sites, generating mRNAs with 5′-UTRs of 215–299 nucleotides, with the predominant isoform containing 238 nucleotides of 5′-UTR sequence. The exon-intron organization is conserved between human, mouse, and rat OPRK1 genes.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.